| Biotres and Bioflux Should be the Product’s That Push Biotricity (BTCY) Into Eight Figure Annual Revenues Near-Term
Good day everyone,
The NASDAQ index tumbled 344 points in the Wednesday session, but BTCY stayed green all day hitting a high of $2.98/share and only fading in the last 30 minutes of trading. I’m excited to see how the company shares trade on a strong NASDAQ day.
We told you earlier that Biotricity, Inc. (NASDAQ: BTCY) just announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. Pre-Orders begin on February 23, 2022, with units shipping April 1, 2022.
Current price $2.76/share (+3.37% at market close 2-23-22)
I looked at the Biotres pre-order form and this is what it said:
Available April 1, 2022! (I note that FYE23 begins on this date)
Biotres is a revolutionary 3 channel Holter and extended Holter patch device that enables you to bill all Holter codes, while reducing report turnaround time. Pre-order yours today. Designed to address the current limitations of existing Holter monitors technologies, Biotres offers the following feature set:
3 Channel Recording – A wearable Holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other known holter patch devices are 1 channel or 2 channels.
Small Form Factor – Overall 4.5″ x 3.5″ Central body is 2.25″ diameter.
Unified Portal – Utilizes the same portal as the Bioflux! One system for all your diagnostic needs!
Rechargeable Battery – It can be worn continuously for 48 hours, in connectivity mode, before needing to be charged for 1 hour, enabling continuous data collection for extended periods of time without any intervention, a distinction not possible with traditional Holter patch solutions.
Wireless Connectivity – Utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current Holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
User-Friendly Design – Easy to understand and comfortable to wear during regular day-to-day activities.
Modular Design – Designed with the flexibility to support our strategy of adding future features and functionality to the Biotres platform.
Unique Business Model – the design of Biotres enables providers to bill directly, creating a revenue stream with a simplified workflow for providers while reducing risk and diagnostic turnaround time for patients.
IMPORTANT! PLEASE NOTE: Once you received your Biotres and start using it, you will be on a flat rate model and will be charged at $125 per month per device. Biotres is a profit center after the first Holter study use! (that’s a $1,500 annual charge)
The company has a network of 1,500 cardiac doctors in 25 states in 350 clinics & 500 offices representing 3 million patients. Biotricity focuses on clinics because 80% of cardiologists are in multi-care groups. Given that BTCY is committed to growing its sales force this year, I expect that number of customers could grow considerably. It is estimated there are over 33,000 cardiologists is the United States and more and more of them are turning to technology-as-a-service implementing remote cardiac data collection.
It would only take the deployment of 7,000 Biotres units to propel the company into an eight figure annual revenue level, and keep in mind, the company has other popular verticals as well.
The Traders News Group
original reports below
Biotricity (BTCY) Guides Toward FYE22 as a Revenue Record Breaker and How FYE23 Could Be Their Breakout Year with New Revenue Streams
Now Taking Pre-Orders for Biotres
Good day everyone,
After closing the Tuesday session at $2.67/share Biotricity, Inc. (NASDAQ: BTCY) gapped at the open to $2.81/share. The share price quickly gained to $2.92 in early trading.
Current price $2.87/share (+ 7.49% as of 10:10 am EST 2-23-22)
In news released this morning, BTCY announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. Pre-Orders begin on February 23, 2022, with units shipping April 1, 2022
Biotres is a wireless three lead cardiac holter monitoring device, an upgrade from the one lead standard currently used by cardiac physicians. Biotres can provide continuous recording of ECG heart data and remote data uploading,
BTCY has a FYE of March 30, so they are now operating in Q422. I urge you, as a part of your due diligence, to review the Q322 BTCY form 10-Q filed on February 14th. While I have given you the highlights, the full 10-Q has a lot of details about the company’s near-term development plans.
Stay tuned for our full report on BTCY,
The Traders News Group
original report below
Biotricity (BTCY) Reports Strong FYQ3 Results and Lays Out Plans for a Breakout Year Ahead
“Look at this local news story where Biotricity’s Bioflux Device saved this man’s life – https://www.youtube.com/watch?v=Jj3LDuNu–w”
Good day everyone and welcome to our new group members,
Last month when we reported on Biotricity, Inc. (NASDAQ: BTCY) I indicated they would be releasing their earnings report in a few weeks. We got the Q3 earnings report (FYE is March 30) on February 14th, 2022 and once again, it was great news.
Current price $2.64/share
BTCY Continues to Achieve Key Milestones
More good news with a recent strong financial report.
The share price is the lowest level I’ve seen in the past nine months, creating what I believe is an anomalous opportunity.
BTCY shares had a high of $5.30/share eleven weeks ago. Returning to that level will represent over 100% in gains for our group from the current levels.
Q322 financial highlights include:
Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- million reported in Q2FY22.
Cash Position of $16.8 M at quarter end is their highest ever.
Scaling well – SG&A rose just 40%, R&D up 32%, compared with 93% revenue increase.
Net loss of $7.34 million or $0.15 per share, impacted by one-time derivative fair value and accretion expenses of $1.34 million during the quarter; excluding these non-recurring items would result in an adjusted net loss of $6.0 million or $0.12 per share.
On track for FYE22 triple digit revenue growth.
Here is the recent growth in BTCY revenues:
FYE 2019 $392K
FYE 2020 $1.41M +259%
FYE 2021 $3.38M +139%
FYE 2022 $7.42M +119% (assumes Q422 revenue is equal to Q322 revenue)
Those figures above represent a cumulative revenue gain, over only three years, of 1,890%. I am hard pressed to think of another company with that level of revenue gains, in that short a period.
Q322 operational milestones:
Bioheart was brought to market, a heart monitor now directly available to consumers on the company website or Amazon.
FDA 510(k) clearance of Biotres, a holter monitor for low-risk patients designed for comfort and long-term wear. It will work with the Bioflux Platform as an additional billable tool for cardiac physicians.
In December, the Company successfully completed a $12 million non-dilutive debt financing on favorable terms.
There is a potential looming market for BTCY products due to covid. As just reported in the Washington Post, recent studies show that people exposed to covid are experiencing irregular pulse rates even months after infection. The studies, published in Nature Medicine, indicate that the risk of cardiovascular disease increased substantially in the year following infection even in mild covid cases, including folks in their 30s and 40s.
Donald M. Lloyd-Jones, president of the American Heart Association has stated publicly “we are expecting a tidal wave of cardiovascular events in the coming years from direct and indirect causes of covid.” I haven’t had covid (knocking on my wooden desk now) but if I’m ever exposed to it I would go to the BTCY website and get a Bioheart Monitor considering the $199 cost a cheap investment in my health.
The NASDAQ index has dropped significantly and BTCY shares have dropped in lockstep with the index, but the four analysts covering BTCY haven’t budged in their opinions. All four analysts have a “buy” rating on the company with a consensus target of $6.75/share representing a 153% upside.
BTCY has experienced fantastic growth but stayed dedicated to building shareholder value as evidenced by maintaining their modest share structure with 49.8M shares outstanding and only 39.5M shares in the public float. Since insiders hold about 7.5M shares, their interest in shareholder value benefits them. Note that The Vanguard Group owns 4.3% of the outstanding shares.
Anticipated and upcoming FY22 catalysts for BTCY:
BIG ONE HERE – Introduction of Bioflux 2.0, the next gen of their flagship platform used by cardiac clinics.
Watch this local news story where Biotricity’s Bioflux Device saved a man’s life – https://www.youtube.com/watch?v=Jj3LDuNu–w
This man is alive because of the Bioflux device reporting a dangerous abnormal heart beat while he was sleeping at 11pm. When this device gets into the broader market, there could be much more stories like this equating to a massive revenue stream for Biotricity.
Growth in the company sales force to push the company cardiac ecosystem beyond the current 1500 cardiac doctors and twenty-six states.
The introduction of advanced ECG analysis software that will analyze accumulated data in seconds.
Commercialization of the Biotres holter monitor.
The current value of BTCY stock doesn’t seem to reflect their level of revenue growth, technology, or their clearly defined milestones and potential catalysts for the year ahead.
We will be back with an updated report soon,
The Traders News Group |
